pharmacopeia

Interstitial Lung Disease

37 drugs12,380 FAERS reportsMedDRA PT
GET
/api/v1/reaction/interstitial-lung-disease
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.

DefinitionNLM MeSH D017563

A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.

Source: U.S. National Library of Medicine — MeSH (Lung Diseases, Interstitial)

Drugs reporting Interstitial Lung Disease (37)

Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.

  1. 1Telisotuzumab36.7%
  2. 2Toremifene225.2%
  3. 3Eribulin1814.9%
  4. 4Naldemedine774.9%
  5. 5Ramucirumab2944.8%
  6. 6Gefitinib4194.7%
  7. 7Datopotamab Deruxtecan163.6%
  8. 8Flutamide293.0%
  9. 9Levoleucovorin1052.9%
  10. 10Vinblastine552.9%
  11. 11Daptomycin2512.8%
  12. 12Tepotinib162.8%
  13. 13Vonoprazan1882.8%
  14. 14Enfortumab1702.6%
  15. 15Avelumab1022.6%
  16. 16Sulbactam642.5%
  17. 17Durvalumab4642.5%
  18. 18Temsirolimus1102.4%
  19. 19Pembrolizumab2,4342.4%
  20. 20Luliconazole42.4%
  21. 21Pemetrexed8842.4%
  22. 22Vincristine6802.4%
  23. 23Cemiplimab432.3%
  24. 24Lemborexant582.3%
  25. 25Tremelimumab882.2%
  26. 26Bleomycin2222.2%
  27. 27Atezolizumab8102.2%
  28. 28Levacetylleucine42.1%
  29. 29Trastuzumab1,8222.1%
  30. 30Miglitol192.0%
  31. 31Alogliptin721.9%
  32. 32Osimertinib5791.9%
  33. 33Olaparib3781.9%
  34. 34Defibrotide621.8%
  35. 35Nivolumab1,6151.7%
  36. 36Mirvetuximab Soravtansine231.6%
  37. 37Epinastine171.5%

Related reactions

Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.

Literature

Recent PubMed references pinned to Lung Diseases, Interstitial as a MeSH major topic. About the reaction term itself — not about any specific drug.

Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.

Search pharmacopeia

Search drugs, classes, and ingredients